BACKGROUND BACKGROUND
• Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease that has multiple signs and symptoms, including inflamed joints and entheses, as well as psoriasis, and can lead to reduced physical function and quality of life for patients. [1] [2] [3] [4] • Effective treatment of PsA has been shown to significantly improve patient outcomes. 5, 6 • Apremilast is an orally administered inhibitor of phosphodiesterase 4, and can modulate the aberrant immune response that causes the signs and symptoms of PsA. 7 • In January 2015, apremilast, alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs), was approved by the European Medicines Agency for the treatment of PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
• The objective of this analysis was to assess the budget impact of introducing apremilast in the current treatment portfolio for PsA from the UK payer perspective.
METHODS METHODS

Model Structure
• A 5-year budget impact model was developed using a prevalence-based approach ( Figure 1 ).
• The analysis was conducted from the perspective of the NHS in the UK. 
Patient Population
• The target population was estimated based on the total UK population, annual population growth rate, and prevalence of PsA.
• The UK adult population size in 2015 and the annual growth rate over the next 5 years was obtained from the Office for National Statistics. [8] [9] • The prevalence of PsA was assumed constant over 5 years. Treatment Options and Uptake of Apremilast
• The target population was divided into 3 categories: untreated patients, patients receiving ≥1 conventional DMARD, and patients on biologics.
• Conventional DMARDs include methotrexate, leflunomide, and cyclosporine.
• Biologics include adalimumab, etanercept, infliximab, golimumab, biosimilar etanercept, and biosimilar infliximab for patients who had an inadequate response to conventional DMARDs.
• In the reference scenario (ie, "world without apremilast"), market shares were assumed to be constant over time.
• As apremilast is indicated in patients who have failed or are intolerant or contraindicated to conventional DMARDs, in the "world with apremilast," it was assumed that the uptake of apremilast would cover only those patients who would be eligible for biologic treatment.
• Therefore, a proportion of patients who would have received biologics were assumed to be treated with apremilast in the "world with" scenario.
• The model assumed an equal displacement of each biologic therapy, ie, the shares taken by apremilast were divided among the biologic agents equally.
METHODS (cont'd) METHODS (cont'd)
Cost Inputs
• Costs were estimated by considering drug acquisition costs, drug administration costs, and monitoring costs (physician visits and laboratory tests). Unit costs were assumed to remain constant over the modelled timeframe.
• Drug costs were quoted from the British National Formulary (BNF) 11 and the Monthly Index of Medical Specialties (MIMS) 12 and were based on licensed dosing included within the SmPCs.
• Administration costs were obtained from the National Clinical Guideline Centre (NCGC); 13 physician visit and laboratory test costs were informed by NHS reference costs, 14 the NCGC, 13 and published literature. [15] [16] 
RESULTS RESULTS
• Over a 5-year period, the number of patients treated with apremilast is estimated to increase from 17 to 1,784.
• The annual overall cost savings was estimated to increase from £44,909 in 2016 to £4,802,692 in 2020 ( Table 3 ).
• The introduction of apremilast decreased the total 5-year budget by 1.1% (£930,289,008 vs £940,614,198) relative to the world without apremilast.
• In 2020, total drug acquisition costs were estimated to decrease by 3.34% (£127,064,953 vs £131,458,297), and administration and monitoring costs decreased by 0.69% (£58,888,850 vs £59,298,198), yielding a net cost savings of 2.52%. 
CONCLUSIONS CONCLUSIONS
• Apremilast is expected to displace a proportion of biologics, offering an alternative option for patients who have failed or are intolerant to conventional DMARD therapy.
• The oral self-administration of apremilast is associated with a reduction of the resource use for drug administration compared with IV-administered biologics and a reduction of resource use for monitoring compared with biologic therapy • Inclusion of apremilast in the PsA treatment regimen in the UK is cost-saving in all respects.
